Streptococcus agalactiae, also known as Group B streptococcus (GBS), is a Gram-positive bacterium that causes a variety of infections in neonates, pregnant women, the elderly, or immunocompromised individuals. S. agalactiae is estimated to cause 1-2% of all single organism urinary tract infections, including cystitis, pyelonephritis, and asymptomatic bacteriuria (ABU). S. agalactiae is able to form biofilms on abiotic and biotic surfaces, protecting it from killing by antibiotics or host immune cells and promoting host colonisation. Here, we define the hemolytic and biofilm-forming activities of a collection of clinical isolates of uropathogenic S. agalactiae (UPSA), ABU-causing S. agalactiae (ABSA), and recurrent S. agalactiae bacteriuria (rSAB) strains to explore these phenotypes in the context of clinical history of isolates. A total of 61 UPSA, 184 ABSA, and 47 rSAB isolates were analysed for hemolytic activity by spot assays on blood agar. Biofilm formation was determined by microtiter plate assay with Lysogeny broth (LB) and Todd-Hewitt broth (THB) supplemented with 1% glucose to induce biofilm formation. We also used multiplex PCR to analyse isolates for the presence of genes encoding pili, which contribute to biofilm formation. Comparing the hemolytic activities of 292 isolates showed that ABSA strains were significantly more likely to be highly hemolytic compared to other strains. In contrast, there were no differences between the relative abilities of strains from the different clinical history groups to form biofilms. The multiplex PCR screen found that there was no difference in the number of strains that possessed the three genes encoding pili across the different clinical history groups. Taken together, these findings demonstrate a propensity of S. agalactiae causing ABU to be highly hemolytic but no link between clinical history of UTI strains and ability to form biofilm.